Celgene Corporation  

(Public, NASDAQ:CELG)   Watch this stock  
Find more results for CELG
124.12
+0.23 (0.19%)
After Hours: 124.39 +0.27 (0.22%)
Jan 26, 7:26PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 122.54 - 124.60
52 week 66.85 - 124.60
Open 123.55
Vol / Avg. 3.79M/6.02M
Mkt cap 99.34B
P/E 64.97
Div/yield     -
EPS 1.91
Shares 798.70M
Beta 1.10
Inst. own 83%
Jan 29, 2015
Q4 2014 Celgene Corp Earnings Release - 9:30AM EST - Add to calendar
Jan 29, 2015
Q4 2014 Celgene Corp Earnings Call - 9:00AM EST - Add to calendar
Jan 12, 2015
Celgene Corp at JPMorgan Healthcare Conference - Q&A Session
Jan 12, 2015
Celgene Corp at JPMorgan Healthcare Conference - Webcast
Jan 12, 2015
Preliminary 2014 Celgene Corp Earnings Release
Dec 7, 2014
Celgene Presentation at the American Society of Hematology - Webcast
Nov 11, 2014
Celgene Corp at Credit Suisse Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 25.65% 22.33%
Operating margin 32.52% 27.86%
EBITD margin - 36.25%
Return on average assets 12.75% 11.55%
Return on average equity 38.41% 25.70%
Employees 5,100 -
CDP Score - 80 C

Address

86 Morris Ave
SUMMIT, NJ 07901-3915
United States - Map
+1-908-6739000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Celgene Corporation is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The Company�s commercial stage products include REVLIMID, VIDAZA, ABRAXANE, POMALYST/IMNOVID, THALOMID, ISTODAX and azacitidine for injection. The Company�s preclinical and clinical-stage pipeline includes Oral anti-inflammatory agents, OTEZLA (apremilast); Next generation thalidomide analogues, CC-122 and CC-220; Cellular therapies, PDA-001 and PDA-002; CC-486; Sotatercept and ACE-536; mTOR pathway inhibitors, CC-223 and CC-115; Epigenetic modifiers, EPZ-5676 and CC-292. Its subsidiaries are Celgene Avilomics Research and Celgene Cellular Therapeutics. The Company collaborated with Acceleron Pharma, Inc. (Acceleron) to develop sotatercept and ACE-536 to treat anemia in patients with rare blood disorders.

Officers and directors

Robert J. Hugin Chairman of the Board, President, Chief Executive Officer
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Mark J. Alles President, Chief Operating Officer
Age: 55
Bio & Compensation  - Reuters
Peter N. Kellogg Chief Financial Officer, Executive Vice President
Age: 58
Bio & Compensation  - Reuters
Jacqualyn A. Fouse Ph.D. President - Hematology & Oncology
Age: 52
Bio & Compensation  - Reuters
Tuomo Patsi President - Europe, Middle East and Africa (EMEA)
Bio & Compensation  - Reuters
Scott Smith President - Inflammation & Immunology
Bio & Compensation  - Reuters
Perry A. Karsen Chief Operations Officer, Executive Vice President
Age: 58
Bio & Compensation  - Reuters
Lawrence V. Stein Executive Vice President, General Counsel, Corporate Secretary
Age: 64
Bio & Compensation  - Reuters
Thomas O. Daniel M.D. Executive Vice President, President - Research and Early Development
Age: 60
Bio & Compensation  - Reuters
Michael D. Casey Lead Independent Director
Age: 68
Bio & Compensation  - Reuters